2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Adverse Events, Biological Processes, Apoptosis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3575 Zanubrutinib plus bendamustine and rituximab(zbr) in newly diagnosed symptomatic Waldenström macroglobulinemia:a phase II study

Wenjie Xiong, Yuting Yan, MD2, Tingyu of Wang3, Weiwei Sui4, Peirou Yan5, Ying Yu6, Tengteng Yu, MD7, Rui Lv, MD8, Yi Wang9, Wei LIU10, Huimin Liu11, Gang An, MD12, Yan Xu, MD13, Wenliang Huang14, Dehui Zou, MD15, Lu-Gui Qiu, PhD16, Shuhua Yi, MD, PhD17
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
16 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China
17 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin 301600, China, Tianjin, China

Introduction:

Waldenström macroglobulinemia (WM) is a rare type of lymphoma, with no optimal treatment. Zanubrutinib, rituximab combined with bendamustine are both first-line treatment options for newly diagnosed symptomatic Waldenström macroglobulinemia (WM). However, continuous BTK inhibitor monotherapy requires lifelong treatment and is associated with suboptimal deep remission rates. The BR regimen has relatively high hematologic toxicity. Therefore, we explore combining zanubrutinib with a reduced-dose BR regimen for the treatment of WM, aiming to achieve a fixed-duration therapy while improving the rate of deep remission in patients.

Methods:

We conducted a phase 2 clinical trial (NCT05914662) to evaluate the efficacy and safety of combining zanubrutinib with a reduced-dose BR regimen (ZBR) in newly diagnosed symptomatic WM patients. Patients received ZBR induction therapy for up to six 28-day cycles, followed by Zanubrutinib consolidation therapy up to total 12 cycles. The primary endpoint was the deep remission rate.

Results:

Overall, 42 of 48 enrolled patients completed induction treatment. Seven patients (16.7%) achieved CR, 21 patients (50%) achieved VGPR, 13 patients (31%%) attained PR. The overall, major and deep remission rates were 97.5%, 97.5% and 67.5%, respectively. The median time to response was 3 months (range, 1-10). Ten patients had CXCR4 mutation, with no disparity in the deep remission between the patients with/without CXCR4 mutation (68.8% vs 60%, P=0.440). Five patients harbored TP53 mutations. Among them, two patients had concurrent 17p deletion. Two patients had isolated 17p deletion. Among the five patients with TP53 mutations, three achieved very good partial response (VGPR) after treatment (60%), and two achieved partial response (PR) (40%). Among the 42 patients, only one patient had 0.04% residual aberrant B lymphocytes after treatment; all other patients had no residual B lymphocytes. 11 patients had residual aberrant plasma cells at the end of treatment. The minimal residual disease (MRD) negativity rate by flow cytometry was 71.4%. MYD88 mutation was assessed in 39 patients. The median baseline MYD88 mutation level was 7.6%. After treatment, MYD88 mutation remained detectable in 13 patients, with a median level of 0.19% (range 0.04–2.5%). Accordingly, the MYD88 negativity rate was 66.7% (26 out of 39 patients). With a median follow-up of 23 months (range, 13-38), only one patient progressed. The median PFS and OS were not reached. The most common AE was hematological toxicity. SAEs were neutropenia (32.6%) and thrombocytopenia (4.3%).

Conclusion:

Overall, ZBR regimen might offer deep remission and provided a time-limited BTKi therarpy in WM patients with manageable AEs
Wenjie Xiong: No relevant conflicts of interest to declare.